Norton Rose Fulbright (London)

Ian Giles

Norton Rose Fulbright (London)
Lawyer (Partner)

Ian is an antitrust and competition lawyer based in London. He focuses in advising on all aspects of competition law with a particular focus on competition and cartel investigations and merger control. Ian has been involved in numerous significant cases in recent years, including acting for Asda in the UK Tobacco investigation and successful appeal; acting for PwC in the UK Audit market investigation; securing EU and other global merger control clearances in Delta/Virgin Atlantic and the $13.6 billion Thermo Fisher/Life Technologies transaction; and representing Stena in securing unconditional clearance before the Competition Commission in Stena/DFDS. Ian has also acted for parties in cartel investigations in the air passenger, air freight; groceries and freight forwarding sectors before UK, EU and other global regulators. Ian was Assistant Director of Competition Policy at the UK Office of Fair Trading (OFT) in 2008-9, which gives him particular insights as to the regulatory approach and perspective. Ian is a frequent speaker and author on competition issues, has been an Editor of Butterworth’s Competition Law and is an active member of the UK International Chamber of Commerce Competition Group. Ian is also a regular media commentator, including with the BBC, CNBC, the Wall Street Journal, the Financial Times, and the Guardian.


Linked authors

Norton Rose Fulbright (Toronto)
Norton Rose Fulbright (New York)
Norton Rose Fulbright (Brussels)
Norton Rose Fulbright (Paris)
Norton Rose Fulbright (Brussels)


949 Bulletin

Ian Giles, Mark Daniels, Shaha El-Sheemy The International Competition Network announces a new set of principles with a view to making antitrust enforcement across jurisdictions more transparent, predictable and consistent


This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. One of the most significant challenges facing companies dealing with the proliferation of global competition regimes is inconsistencies in approach, timelines, (...)

Ian Giles, Clio Angeli The UK Competition Appeal Tribunal partly annuls the Competition Authority’s decision that pharmaceutical companies abused their dominant position by setting excessive and unfair prices for an epilepsy drug (Pfizer / Flynn)


This article has been nominated for the 2019 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On 7 June 2018, the Competition Appeal Tribunal (CAT) set aside in part the 2016 decision of the Competition and Markets Authority (CMA) that Pfizer and Flynn (...)

Send a message